Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study

Published
16 February 2017
By
Carole Leach-Lemens
Experimental STI prophylaxis in PrEP users produces big drops in syphilis and chlamydia infections but not in gonorrhoea

Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men (MSM) taking part in the Ipergay HIV pre-exposure prophylaxis (PrEP)

Published
15 February 2017
By
Gus Cairns
Turning the tide on HIV in Zimbabwe, one AIDS denialist at a time

How does a country—with a history of AIDS-denialism in government, and a financial crisis spanning 10 years—turn the tide on AIDS?

Published
15 February 2017
From
BETA blog
Changes in viral suppression over time reveal disparities in HIV care in the United States

Sustained viral suppression over the course of a year may be a better measure than the most recent viral load test result when it comes to understanding

Published
15 February 2017
By
Liz Highleyman
Dual antiretroviral regimen maintains durable HIV suppression after switch

People who switched from standard antiretroviral therapy (ART) to a two-drug regimen of dolutegravir (Tivicay) plus rilpivirine (Edurant) were able to maintain an undetectable viral load

Published
15 February 2017
By
Liz Highleyman
Infants treated within days of birth can clear HIV reservoir rapidly

Viral load and viral DNA fall rapidly in infants who begin antiretroviral therapy (ART) within days of birth, two South African studies have found, showing the potential

Published
15 February 2017
By
Keith Alcorn
Treatment-as-prevention study sees substantial levels of transmitted drug resistance in participants, but no impact on treatment

A study of the prevalence of transmitted drug resistance in participants in the ANRS 12249 trial of treatment as prevention, which reported its main results at the International

Published
15 February 2017
By
Gus Cairns
Integrase inhibitor bictegravir matches dolutegravir for first-line HIV treatment

Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivicay) in a phase 2 clinical trial, according to

Published
14 February 2017
By
Liz Highleyman
Cake, candles and a wish for more HIV cures

An HIV workshop pays tribute to Timothy Ray Brown, whose cure 10 years ago fueled research — and hope

Published
14 February 2017
From
Fred Hutch
US: Should People With HIV Stock Up on Meds in Fear of Health Care Cuts?

As the Trump admimistration and Congress discuss sweeping changes to health care, should people with HIV start squirreling away their meds in case they lose access? HIV advocates say don't panic -- you'll likely be fine. But there are still things you can think about and steps you can take.

Published
13 February 2017
From
The Body

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.